Gilead Sciences, Inc. $GILD Shares Bought by Exchange Traded Concepts LLC

Key Points

• Exchange Traded Concepts LLC increased its stake in Gilead Sciences by 8.7%, acquiring 11,425 additional shares, bringing its total holdings to 142,076 shares worth approximately $15.75 million.
• A recent wave of upgrades from various analysts has positively influenced Gilead's stock outlook, with target prices raised significantly to as high as $145, resulting in a consensus rating of "Moderate Buy."
• Gilead Sciences announced a quarterly dividend of $0.79 per share, with a dividend yield of 2.8%, set to be paid on September 29th, reflecting a commitment to returning value to shareholders.

Exchange Traded Concepts LLC raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 8.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 142,076 shares of the biopharmaceutical company's stock after purchasing an additional 11,425 shares during the period. Exchange Traded Concepts LLC's holdings in Gilead Sciences were worth $15,752,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in GILD. Price T Rowe Associates Inc. MD grew its stake in Gilead Sciences by 314.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company's stock valued at $1,647,484,000 after acquiring an additional 11,156,382 shares during the period. Nuveen LLC bought a new stake in Gilead Sciences in the first quarter valued at approximately $620,415,000. GAMMA Investing LLC raised its stake in Gilead Sciences by 13,891.1% in the first quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company's stock valued at $285,761,000 after buying an additional 2,532,070 shares during the period. Los Angeles Capital Management LLC raised its stake in Gilead Sciences by 422.6% in the first quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company's stock valued at $282,706,000 after buying an additional 2,040,261 shares during the period. Finally, Vanguard Group Inc. raised its stake in Gilead Sciences by 1.7% in the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company's stock valued at $13,162,606,000 after buying an additional 1,942,433 shares during the period. 83.67% of the stock is owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the sale, the insider directly owned 114,168 shares of the company's stock, valued at $13,532,333.04. The trade was a 19.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the completion of the sale, the chief executive officer directly owned 595,725 shares of the company's stock, valued at $67,692,231.75. The trade was a 1.65% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 82,000 shares of company stock worth $9,390,030 in the last 90 days. 0.27% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of brokerages recently issued reports on GILD. Royal Bank Of Canada increased their price target on Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research report on Friday, August 8th. Rothschild & Co Redburn increased their price target on Gilead Sciences from $136.00 to $143.00 and gave the stock a "buy" rating in a research report on Friday, September 12th. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a research report on Friday, July 25th. Truist Financial raised Gilead Sciences from a "hold" rating to a "buy" rating and raised their target price for the company from $108.00 to $127.00 in a report on Friday, August 8th. Finally, JPMorgan Chase & Co. raised their target price on Gilead Sciences from $135.00 to $145.00 and gave the company an "overweight" rating in a report on Tuesday. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $117.17.

Gilead Sciences Stock Up 0.4%

GILD stock traded up $0.47 during mid-day trading on Friday, reaching $114.09. 12,580,487 shares of the company traded hands, compared to its average volume of 5,841,828. Gilead Sciences, Inc. has a fifty-two week low of $81.83 and a fifty-two week high of $121.83. The firm's 50 day moving average price is $114.10 and its 200 day moving average price is $110.06. The stock has a market cap of $141.56 billion, a price-to-earnings ratio of 22.73, a P/E/G ratio of 0.77 and a beta of 0.36. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Monday, September 15th. Gilead Sciences's payout ratio is currently 62.95%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.